Outpatient treatment trial of mild and severe hypertension

Not much is known about the feasibility or the advantages of treatment of subjects with only mild hypertension. There are also many unresolved problems in the out-patient management of hypertension of any severity. In this study an analysis is made of the results of a controlled treatment trial of 56 subjects with mild hypertension, 26 of whom were treated with active drug and 30 initially with placebo, and a treatment programme involving 81 patients with moderate or severe hypertension, all of whom received treatment with active drug. The drugs used in this study were bethanidine, debrisoquine, and guanethidine. Follow-up for 12 months or more was achieved in 87 percent of individuals admitted to the study with mild hypertension and in 80 percent with severe hypertension. Many subjects with only mildly raised blood pressure were found to have cardiac enlargement on chest x-ray (up to 45 percent) and left ventricular hypertrophy on electrocardiogram (up to 51 percent). Rapid rates of rise of blood presure were observed in many placebo-treated subjects; but good blood pressure control was achieved in 63 out of 104 patients (61 percent) receiving active drug in both the mild and the severe hypertension groups. The drugs used showed approximately equal effectiveness in controlling blood pressure (AU)

The effectiveness of C1-433 versus entero-vioform in the control of diarrhoeal disease

The data indicate that CI-433 was as well accepted as entero-vioform. A comparison between CI-433 and entero-vioform on day 5 for control of diarrhoea indicated no significant difference in the average consistency of stools or in the average number of stools. However, on day 10, entero-vioform showed a better average consistency in stools and also a smaller average number ofstools per day. Stool examination on day 5 for the two medication groups showed CI-433 had eliminated E.histolytica in a higher proportion of patients than did entero-vioform; CI-433 eliminated G.lamblia in the same proportion of patients as, entero-vioform; and CI-433 eliminated less in Shigella patients than entero-vioform. On day 10 entero-vioform, when compared to CI-433 (day 5), was slightly more effective in the elimination of E.histolytica, G.lamblia and Shigella (AU)